https://scholars.lib.ntu.edu.tw/handle/123456789/514735
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Fruchart J.-C. | en_US |
dc.contributor.author | Santos R.D. | en_US |
dc.contributor.author | Aguilar-Salinas C. | en_US |
dc.contributor.author | Aikawa M. | en_US |
dc.contributor.author | Al Rasadi K. | en_US |
dc.contributor.author | Amarenco P. | en_US |
dc.contributor.author | Barter P.J. | en_US |
dc.contributor.author | Ceska R. | en_US |
dc.contributor.author | Corsini A. | en_US |
dc.contributor.author | Despr?s J.-P. | en_US |
dc.contributor.author | Duriez P. | en_US |
dc.contributor.author | Eckel R.H. | en_US |
dc.contributor.author | Ezhov M.V. | en_US |
dc.contributor.author | Farnier M. | en_US |
dc.contributor.author | Ginsberg H.N. | en_US |
dc.contributor.author | Hermans M.P. | en_US |
dc.contributor.author | Ishibashi S. | en_US |
dc.contributor.author | Karpe F. | en_US |
dc.contributor.author | Kodama T. | en_US |
dc.contributor.author | Koenig W. | en_US |
dc.contributor.author | Krempf M. | en_US |
dc.contributor.author | Lim S. | en_US |
dc.contributor.author | Lorenzatti A.J. | en_US |
dc.contributor.author | McPherson R. | en_US |
dc.contributor.author | Nu?ez-Cortes J.M. | en_US |
dc.contributor.author | Nordestgaard B?.G. | en_US |
dc.contributor.author | Ogawa H. | en_US |
dc.contributor.author | Packard C.J. | en_US |
dc.contributor.author | Plutzky J. | en_US |
dc.contributor.author | Ponte-Negretti C.I. | en_US |
dc.contributor.author | Pradhan A. | en_US |
dc.contributor.author | Ray K.K. | en_US |
dc.contributor.author | Reiner Z. | en_US |
dc.contributor.author | Ridker P.M. | en_US |
dc.contributor.author | Ruscica M. | en_US |
dc.contributor.author | Sadikot S. | en_US |
dc.contributor.author | Shimano H. | en_US |
dc.contributor.author | Sritara P. | en_US |
dc.contributor.author | Stock J.K. | en_US |
dc.contributor.author | TA-CHEN SU | en_US |
dc.contributor.author | Susekov A.V. | en_US |
dc.contributor.author | Tartar A. | en_US |
dc.contributor.author | Taskinen M.-R. | en_US |
dc.contributor.author | Tenenbaum A. | en_US |
dc.contributor.author | Tokg?zo?lu L.S. | en_US |
dc.contributor.author | Tomlinson B. | en_US |
dc.contributor.author | Tybj?rg-Hansen A. | en_US |
dc.contributor.author | Valensi P. | en_US |
dc.contributor.author | Vrabl?k M. | en_US |
dc.contributor.author | Wahli W. | en_US |
dc.contributor.author | Watts G.F. | en_US |
dc.contributor.author | Yamashita S. | en_US |
dc.contributor.author | Yokote K. | en_US |
dc.contributor.author | Zambon A. | en_US |
dc.contributor.author | Libby P. | en_US |
dc.creator | Fruchart J.-C.;Santos R.D.;Aguilar-Salinas C.;Aikawa M.;Al Rasadi K.;Amarenco P.;Barter P.J.;Ceska R.;Corsini A.;Despr?S J.-P.;Duriez P.;Eckel R.H.;Ezhov M.V.;Farnier M.;Ginsberg H.N.;Hermans M.P.;Ishibashi S.;Karpe F.;Kodama T.;Koenig W.;Krempf M.;Lim S.;Lorenzatti A.J.;Mcpherson R.;Nu?Ez-Cortes J.M.;Nordestgaard B?.G.;Ogawa H.;Packard C.J.;Plutzky J.;Ponte-Negretti C.I.;Pradhan A.;Ray K.K.;Reiner Z.;Ridker P.M.;Ruscica M.;Sadikot S.;Shimano H.;Sritara P.;Stock J.K.;Ta-Chen Su;Susekov A.V.;Tartar A.;Taskinen M.-R.;Tenenbaum A.;Tokg?Zo?Lu L.S.;Tomlinson B.;Tybj?Rg-Hansen A.;Valensi P.;Vrabl?K M.;Wahli W.;Watts G.F.;Yamashita S.;Yokote K.;Zambon A.;Libby P. | - |
dc.date.accessioned | 2020-09-28T02:47:22Z | - |
dc.date.available | 2020-09-28T02:47:22Z | - |
dc.date.issued | 2019 | - |
dc.identifier.issn | 1475-2840 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85066822428&doi=10.1186%2fs12933-019-0864-7&partnerID=40&md5=86ea08c85ae32a4eaefffc68f64c90a1 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/514735 | - |
dc.description.abstract | In the era of precision medicine, treatments that target specific modifiable characteristics of high-risk patients have the potential to lower further the residual risk of atherosclerotic cardiovascular events. Correction of atherogenic dyslipidemia, however, remains a major unmet clinical need. Elevated plasma triglycerides, with or without low levels of high-density lipoprotein cholesterol (HDL-C), offer a key modifiable component of this common dyslipidemia, especially in insulin resistant conditions such as type 2 diabetes mellitus. The development of selective peroxisome proliferator-activated receptor alpha modulators (SPPARMα) offers an approach to address this treatment gap. This Joint Consensus Panel appraised evidence for the first SPPARMα agonist and concluded that this agent represents a novel therapeutic class, distinct from fibrates, based on pharmacological activity, and, importantly, a safe hepatic and renal profile. The ongoing PROMINENT cardiovascular outcomes trial is testing in 10,000 patients with type 2 diabetes mellitus, elevated triglycerides, and low levels of HDL-C whether treatment with this SPPARMα agonist safely reduces residual cardiovascular risk. ? 2019 The Author(s). | - |
dc.publisher | BioMed Central Ltd. | - |
dc.relation.ispartof | Cardiovascular Diabetology | - |
dc.subject | Atherogenic dyslipidemia; Diabetes; Inflammation; Pemafibrate (K-877); PROMINENT; Remnant cholesterol; Residual cardiovascular risk; Selective peroxisome proliferator-activated receptor alpha modulator; SPPARMalpha; Triglycerides; Visceral obesity | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | high density lipoprotein cholesterol; peroxisome proliferator activated receptor alpha agonist; triacylglycerol; (R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acid; antilipemic agent; benzoxazole derivative; biological marker; butyric acid derivative; lipid; peroxisome proliferator activated receptor alpha; PPARA protein, human; atherogenesis; cardiometabolic risk; cardiovascular risk; conceptual framework; coronary artery atherosclerosis; disease association; disease exacerbation; drug efficacy; drug safety; dyslipidemia; high risk patient; human; lipoprotein metabolism; non insulin dependent diabetes mellitus; nonalcoholic fatty liver; population research; preclinical study; prevalence; Review; risk factor; risk reduction; treatment outcome; treatment planning; triacylglycerol blood level; animal; blood; cardiovascular disease; consensus; dyslipidemia; metabolism; molecularly targeted therapy; patient safety; risk assessment; signal transduction; Animals; Benzoxazoles; Biomarkers; Butyrates; Cardiovascular Diseases; Consensus; Dyslipidemias; Humans; Hypolipidemic Agents; Lipids; Molecular Targeted Therapy; Patient Safety; PPAR alpha; Risk Assessment; Risk Factors; Signal Transduction; Treatment Outcome | - |
dc.title | The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: Conceptual framework and therapeutic potential | en_US |
dc.type | review | en |
dc.identifier.doi | 10.1186/s12933-019-0864-7 | - |
dc.identifier.pmid | 31164165 | - |
dc.identifier.scopus | 2-s2.0-85066822428 | - |
dc.relation.pages | 71 | - |
dc.relation.journalvolume | 18 | - |
dc.relation.journalissue | 1 | - |
item.cerifentitytype | Publications | - |
item.fulltext | no fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.openairetype | review | - |
item.grantfulltext | none | - |
crisitem.author.dept | Environmental and Occupational Medicine | - |
crisitem.author.dept | Environmental and Occupational Medicine-NTUH | - |
crisitem.author.orcid | 0000-0001-7523-7166 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。